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Compouud Inhibition Pattern K i., (~M) KH,(I-lMl 
lIexachlorophene Uncompetitive"'O -- 12 ± 1 
(Fig. I, C.) 
Dichlorophene Noncompetitive"'C 40± 8 78 ± 8 
(Fig. 2, D.). 
Dichlorophene Uncompetitive",a 20 ± 1 
(Fig. 2, D.). 
Triclosan Uncompetitive",b -- 0.23 ± 0,01 
(Fig. 3, E.) 
"Studies were done with a fixed NADPH concentration of 50 ~M, varied menadione concentrations ranging 
from 12 to 125 )lM in 100 mM sodium phosphate buffer, pH=7,O, 
VA bData fit best to the uncompetitive inhibition model va = I where A is the concentration of 
A(1 +-) + Kill 
Kii 
menadione, I is the inhibitor concentration, V is the maximal velocity, Km is the Michaelis constant for 
menadione and Kii is the intercept inhibition constant. 
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where A is the 
concentration of menadione, I is the inhibitor concentration, V is the maximal velocity, Km is the Michaelis 
constant for menadione, Kii is the intercept inhibition constant, and Kis is the slope inhibition constant. 
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BIPHENYL INHIBITORS OF CARBONYL 
REDUCTASE 
Some activities related to this invention were conducted 
with support by National Institute of Health, NIH/ 
P20RR16454. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to compositions of matter, and meth-
ods of using said compositions for inhibiting enzyme(s) that 
destroy the cell-killing efficacy of cancer drugs and/or that 
catalyze the formation of dangerous or damaging metabolites 
during or after cancer treatment. More specifically, preferred 
embodiments of the invented compositions and methods 
inhibit human carbonyl reductase, thus inhibiting conversion 
of anthracycline to metabolites that are less effective cell-
killing agents and that also lead to cardiotoxicity during or 
after treatment of cancer patients. Thus, the preferred com-
positions and methods are believed to lower the amount 
needed, and the cardiotoxic side-effects, of anthracyclines in 
cancer treatment. 
2. Related Art 
2 
is largely because the alcohol metabolites of anthracyclines 
have been shown to exhibit significantly lowered anticancer 
properties. Relevant to this are studies performed by Tanaka, 
et aI., (reported in Tanaka, et aI., "An Unbiased Cell Morphol-
ogy-Based Screen for New, Biologically Active Small Mol-
ecules," PLoS Biology, Vol. 3, Iss. 5, 0764-0776, May 2005). 
Tanaka, et al. report that a potent inhibitor of human carbonyl 
reductase (3 -(7 -isopropy 1-4-(methy lamino )-7H -pyrrolo [2,3-
d]pyrimidin-5-yl) phenol, when coadministered with dauno-
10 rubicin to A549 adenocarcinoma cells, was found to enhance 
the cytotoxicity of daunorubicin. It was concluded that inhi-
bition of carbonyl reductase led to enhanced cytotoxicity of 
daunorubicin. 
See, for example, the FIG. 2 representation of carbonyl 
15 reductase catalysis (reduction via NADPH+H+ mechanism) 
of the anthracycline daunorubicin to daunorubicinol. While 
daunorubicin is an effective anti-cancer agent by means of its 
effective disruption of DNA replication, daunorubicinol 
exhibits reduced anti-cancer properties and is a potent car-
20 diotoxin. Therefore, conversion to the alcohol metabolite not 
only creates a potent cardiotoxin, but also lowers the efficacy 
of the treatment for a given amount of anthracycline. 
Therefore, the inventor believes that there is a need for 
pharmaceutical interventions that block the action of human 
25 carbonyl reductase. The inventor believes that such pharma-
ceutical interventions will increase the efficacy of anthracy-
cline therapy in cancer/tumor treatment by preventing or low-
ering conversion of anthracyclines to less potent cell-killing 
species and by reducing the risk of cardiotoxicity. 
Anthracyclines are a family of drugs that are effective 
anti-neoplastic agents, and are commonly used to treat can-
cer, including leukemia, soft tissue sarcomas, and breast and 
lung cancer. Anthracyclines intercalate into DNA and are 
described as topoisomerase Type II poisons. The anthracy-
cline family comprises adriamycin, daunomycin, daunorubi- 30 
cin, doxorubicin, epirubicin, and idarubicin. See, for 
example, representations of doxorubicin and daunorubicin in 
FIG. 1. 
SUMMARY OF THE INVENTION 
The present invention comprises compositions of matter 
that include inhibitors of human enzymes. The preferred While the anthracyclines are known to be potent anti -tumor 
drugs, their use has been limited due to potentially life-threat-
ening cardiotoxicity associated therewith. This problem may 
be described as cumulative dose-dependent cardiotoxicity, 
which can ultimately result in congestive heart failure. There 
is significant evidence that the toxic effects on the heart asso-
ciated with anthracycline-based cancer treatment are largely 
attributable to anthracycline alcohol metabolite(s) that can 
form and accumulate in cardiac cells. These metabolites are 
known to disrupt several key processes in heart muscle and 
thus impair heart function. See, for example, Minotti, et aI., 
"Anthracyclines: Molecular Advances and Pharmacologic 
Developments in Antitumor Activity and Cardioitoxicity," 
Pharmacological Reviews, 56: 185-229,2004. 
Enzymes belonging to the aldo-keto reductase and short 
chain dehydrogenase/reductase protein superfamilies cata-
lyze the formation of the anthracycline metabolites. Of these 
enzymes, carbonyl reductase ("CR") has been specifically 
linked to the development of anthracycline-induced car-
diotoxicity. See, for example, Olson, et aI., "Protection from 
Doxorubicin-Induced Cardiac Toxicity in Mice with a Null 
Allele of Carbonyl Reductase 1," Cancer Research, 63,6602-
6606, Oct. 15,2003. Findings that support the hypothesis that 
CR is a key factor in anthracycline-induced cardiotoxicity 
include studies wherein heart-specific over-expression of 
human carbonyl reductase in transgenic mice substantially 
increased the development of cardiotoxicity after anthracy-
cline treatment. See, for example, Forrest, et aI., "Human 
Carbonyl Reductase Overexpression in the Heart Advances 
the Development of Doxorubicin-induced Cardiotoxicity in 
Transgenic Mice," Cancer Research, 60,5158-5164, Sep. 15, 
2000. 
Further, several studies have implicated the reduction of 
anthracyclines by carbonyl reductase in drug resistance. This 
35 embodiments comprise compositions of matter, and methods 
of treating patients, that prevent or lower conversion in the 
human body of cancer drugs to metabolites that are less 
effective for cancer treatment and/or that are believed to pro-
duce cardiotoxicity during or after cancer treatment. Hence, 
40 by using preferred embodiments of the invented composi-
tions and/or methods, the effectiveness of a given dose of 
anthracycline drugs may increase, and the risk of cardiotox-
icity typically associated with said treatment may lessen. 
Embodiments of the invention may comprise compositions 
45 or treatments for, and/or methods of, inhibiting one or more 
enzymes from the groups referred to as aldo-keto reductase 
and short chain dehydrogenase/reductase protein superfami-
lies. Preferably, embodiments of the invention comprise com-
positions or treatments for, and/or methods of, inhibiting 
50 enzyme(s) that catalyze anthracycline conversion to anthra-
cycline metabolites, wherein carbonyl reductase ("CR") is 
especially implicated as described in the Related Art section 
above. Preferably, this inhibition also has the direct effect of 
maintaining concentrations of anthracyclines, which are 
55 desirable for their cell-killing abilities, and, hence, for their 
cancer-cell-killing abilities. Preferably, this inhibition also 
has a indirect effect oflowering formation of metabolites that 
build up during or after treatment with anthracycline cancer 
drugs, said metabolites being ones that are believed to disrupt 
60 heart muscle processes and therefore to interfere with heart 
function. Therefore, by using preferred embodiments of the 
invented compositions and/or methods, much less anthracy-
cline drug is expected to be needed to achieve the desired 
killing of cells, and much less cardiotoxic metabolite will be 
65 produced over the duration of the cancer treatment. 
The invented compositions comprise compounds having at 
least one aryl (preferably phenyl) group, wherein at least one 
US 7,781,412 B2 
3 
of said at least one aryl/phenyl group comprises one or more 
halogen, pseudo-halogen, and/or hydroxyl group. In the pre-
ferred embodiments disclosed herein, the compositions com-
prise compounds having at least two aryl (preferably phenyl) 
groups, wherein at least one of said at least two aryl/phenyl 
groups comprises one or more halogen, pseudo-halogen, and/ 
or hydroxyl group. 
4 
In especially-preferred embodiments, two halogenated, 
pseudo-halogenated and/or hydroxylated aryl/phenyl groups 
are connected by a bridging carbon, oxygen, sulfur, nitrogen, 10 
or derivative of carbon, oxygen, sulfur, or nitrogen, wherein at 
least one of said aryl/phenyl groups comprises at least one 
halogen, pseudo-halogen, or hydroxyl group. Especially-pre-
ferred embodiments comprise one or more biphenyl com-
ponnds selected from the group consisting of: triclosan, 15 
hexachlorophene, dichlorophene, bithionol, bithionol sulfox-
ide, and derivatives thereof. The biphenyl componnds may be 
administered to a human (or other mammal) in a pharmaceu-
tical composition also comprising at least one anthracycline 
compound, or may be administered separately from the at 20 
least one anthracycline componnd either at the same time as 
the anthracycline(s), or any different time found to be effec-
tive for inhibiting formation of the anthracycline metabolites. 
FIG. 8 snnnnarizes data showing that all of the inhibitors 
bind to enzyme forms distinct from those to which menadione 
binds, as determined from inhibition studies such as those 
represented in FIGS. 4-7. The inhibitors (represented by "I") 
dichlorophene, hexachlorophene, and triclosan may bind to 
free enzyme, ternary and/or the enzyme-NADP+ binary com-
plex. Enzyme (CR) is represented by "E". Menadione could 
be replaced by anthracyclines or other carbonyl-containing 
substrates, so that menadione may be considered a substitute 
or surrogate for anthracyclines or other carbonyl-containing 
substrates in these studies. 
FIG. 9 shows a graph indicating that addition of increasing 
concentrations oftriclosan lowers the ICso of doxorubicin in 
killing breast cancer cells (MDA cell line ). Cell viability was 
determined by uptake of alomar blue. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Referring to the figures, there are shown several, but not the 
only, embodiments of the invented composition of matter and 
methods for enhancing the efficacy of anthracycline drug 
cancer treatment and/or limiting side-effects thereof. The 
preferred methods and compositions of matter may maintain Therefore, an object of the preferred embodiments is to 
inhibit one or more of the members of the aldo-keto reductase 25 effective concentrations of anthracycline(s) during cancer 
treatment, by preventing or lowering conversion of the 
anthracycline(s) to metabolites that are less effective or inef-
fective as cancer-cell-killing species. The preferred methods 
and compositions may also prevent or lower the potentially 
and/or short chain dehydrogenase/reductase protein super-
families that catalyze conversion of anthracycline to anthra-
cycline metabolites. The preferred embodiments inhibit 
human carbonyl reductase and are expected to produce the 
synergistic effects of reducing cardiotoxicity from anthracy-
cline chemotherapy and also lowering dosages of the anthra-
cycline drug that will be effective for cancer-cell-killing. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a representation of an anthracycline compound, 
which may be doxorubicin (R OH) or daunorubicin 
(R H), wherein the arrow designates the carbon at position 
13. 
FIG. 2 is a representation of a carbonyl reductase-
NADPH mechanism for reducing the anthracycline dannoru-
bicin to the anthracycline alcohol metabolite dannorubicinol. 
FIGS. 3A-F show the chemical structures of several biphe-
nyl inhibitors (FIGS. 3A-E) of carbonyl reductase according 
to embodiments of the invention and a representation of a 
general structure (FI G. 3 F) expected to lead to other carbonyl 
reductase inhibitors with the scope of the invention. FIGS. 
3A-E illustrate: 3A. Bithionol, 3B. Bithionol Sulfoxide, 3C. 
Hexachlorophene, 3D. Dichlorophene, and 3E. Triclosan. In 
the representation of a general structure of FIG. 3F, R1=C, S, 
0, N and all derivatives; R2=hydrogen, halogen, alcohol, 
pseudohalogen; and carbons in the phenyl ring may also be 
replaced by N, S, and/or O. 
FIG. 4 is a graph showing that dichlorophene is a noncom-
petitive inhibitor against menadione, when the NADPH con-
centration is fixed at 50 flM. 
FIG. 5 is a graph showing that hexachlorophene is an 
uncompetitive inhibitor against menadione, when the 
NADPH concentration is fixed at 50 flM. 
FIG. 6 is a graph showing that triclosan is an nncompetitive 
inhibitor against menadione, when the NADPH concentra-
tion is fixed at 50 flM. 
FIG. 7 describes inhibition patterns seen with inhibitors 
dichlorophene, hexachlorophene, and triclosan wherein KIS 
and KII stand for the slope and intercept inhibition constants, 
respectively. 
30 life-threatening cardiotoxicity associated with anthracycline 
chemotherapy for cancer patients. 
Some embodiments of the invention may include compo-
sitions, and/or methods of using the compositions in cancer 
treatment, that comprise one aryl (preferably phenyl) group, 
35 for example, a halogenated aryl group, oximino(2,4-difluo-
rophenyl)acetonitrile, oximino(2,6-difluorophenyl)acetoni-
trile, oximino(2,5-difluorophenyl)acetonitrile, oximino(2-
chloro-6-fluorophenyl)acetonitrile, oximino(2,4-
dichlorophenyl)acetonitrile, oximino(2,6-dichlorophenyl) 
40 acetonitrile, and/or mixtures of two or more thereof, as 
disclosed in Patent Application Ser. No. 60/830,293 and Ser. 
No. 111776,536. However, embodiments of the invention that 
are expected to show superior results in the treatment of 
cancer may be described as those comprising at least two 
45 (preferably two) aryl or phenyl groups, and, especially, those 
that are disclosed in Patent Application Ser. No. 601776,269 
and Ser. No. 111711,490 and that are disclosed herein. There-
fore, the preferred compounds that are expected to provide 
superior results for use in the above-described prevention or 
50 lowering of anthracycline conversion have at least two aryl 
(preferably phenyl) groups, wherein at least one of the aryl/ 
phenyl groups has at least one halogen, pseudo-halogen or a 
hydroxyl group as a substituent. Pseudo-halogens may 
include binary inorganic compounds of the general form XY, 
55 where X is a cyanide, cyanate, or thiocyallate and where Y is 
any of X or a true halogen, including but not limited to 
cyanogen ((CN)2) and iodine cyanide (lCN). Preferably, 
biphenyl componnds that are halogenated or pseudo-haloge-
60 
nated also comprise at least one hydroxyl group. 
The especially-preferred embodiments comprise one or 
more substituted biphenyl compounds, and preferably one or 
more of the following compounds: triclosan, hexachlo-
rophene, dichlorophene, and, as previously described in 
Patent Application Ser. No. 601776,269 and Ser. No. 111711, 
65 490, bithionol, bithionol sulfoxide, and derivatives thereof. 
See FIGS. 3A-E. Also, it is expected that derivatives or ana-
logs of these compounds may be effective in the place of one 
US 7,781,412 B2 
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or more of these compounds, or as a supplement to one or 
more of these compounds. Considering the structures of the 
triclosan, hexachlorophene, and dichlorophene and bithionol 
and bithionol sulfoxide from patent application Ser. No. 
111711,490, an overall general structure (biphenyl com-
pound) for possible carbonyl reductase inhibitors is envi-
sioned. This biphenyl compound general structure is depicted 
in FIG. 3F and compounds fitting this general structure are 
also expected to prevent or hinder anthracycline conversion in 
embodiments of the invention. 
The compounds and general structure illustrated in FIGS. 
3A-F may further be described by the following Table 1: 
Figure No. 
3A 
3B 
3C 
3D 
3E 
3F 
TABLE 1 
Names 
Bithionol, 2,2'-Thio-bis(4,6-dichlorophenol), 
Bis(2-hydroxy-3 ,5-dichlorophenyl) sulfide 
Bithionol Sulfoxide, 2,2'-Sulfinyl-bis (4,6-
dichlorophenol) 
Hexachlorophene,2,2'-Methylenebis(3,4,6-
trichlorophenol) 
Dichlorophene, Bis(5-chloro-2-hydroxphenyl)methane, 
Dichlorophen 
Triclosan,5-Chloro-2-(2,4-dichlorophenoxy)phenol, 
Irgasan 
A General Structure, wherein Rl = C, S, 0, N 
and/or all derivatives; wherein R2 = hydrogen, 
halogen, alcohol (hydroxyl), and/or pseudohalogen; 
and wherein carbons in the phenyl ring may be re-
placed by N, Sand/or O. (Note that, while the ring 
structures of FIG. 3F are portrayed in the conven-
tional manner as six- carbon ring structures, one 
or more of the carbons of one or both of said six-
carbon ring structures may be replaced by nitrogen, 
sulfur, and/or oxygen, and may not have hydrogen or 
substituent groups). 
It may be noted that carbon of the aryl/phenyl rings shown 
in FIG. 3F may be replaced by N, S, and/or O. It may also be 
noted that one or more halogen, pseudo-halogen and/or alco-
hol groups may be substituent groups bound to all or some of 
the carbons of one or both of the aryl/phenyl rings of the 
preferred compounds, but that carbon sites (carbons of the 
aryl-phenyl rings) may also have no substituent group (hence, 
"unsubstituted") and would comprise hydrogen bound to said 
carbon sites, as will be understood by one skill in the art. The 
atom/compound bridging the aryl/phenyl groups may be car-
bon, oxygen, sulfur, nitrogen, or derivative of carbon, oxy-
gen, sulfur, or nitrogen. 
Use of Preferred Compositions as Enzyme Inhibitors 
6 
In addition, because the anthracycline metabolite(s) are 
believed to not possess the anti-neoplastic properties of the 
parent anthracycline(s), carbonyl reductase may also contrib-
ute to anthracycline drug resistance. In other words, carbonyl 
reductase may lower anthracycline concentrations in the 
human body by catalyzing conversion of the anthracycline, 
and, hence, may lower the amount of cancer cells killed by a 
given dose of anthracycline drug. 
Several biphenyl compounds, namely, triclosan, hexachlo-
10 rophene, dichlorophene and those identified in Ser. Nos. 
601776,269 and Ser. No. 111711,490, have been shown by the 
inventor to inhibit carbonyl reductase, and are envisioned to 
allow an increase in anthracycline chemotherapy by offset-
ting the negative side effects of this chemotherapy. Also, as 
15 discussed above, the preferred compositions and methods 
may decrease anthracycline drug resistance, further improv-
ing the results of anthracycline chemotherapy. 
Specifically, referring to FIGS. 4-6, triclosan, hexachlo-
rophene, and dichlorophene have been shown by the inven-
20 tors to be uncompetitive inhibitors (noncompetitive for 
dichlorophene) carbonyl substrates, with inhibition constant 
values ranging from 0.23-78 flM. These preferred compounds 
have been seen to exhibit inhibition patterns suggestive of 
binding to multiple enzyme forms, which may mean that 
25 increased anthracycline dosages may not overcome the inhi-
bition. See FIGS. 4-6, which comprise data from laboratory 
testing using menadione. Menadione could be replaced by 
anthracyclines or other carbonyl-containing substrates, so 
that menadione may be considered a substitute or surrogate 
30 for anthracyclines or other carbonyl-containing substrates in 
these studies, and, hence, indicative of expected performance 
regarding anthracyclines. 
Triclosan, hexachlorophene, and dichlorophene are known 
antibiotics. For examples see the following literature: 
35 Kim, Woo-Jae; Oh, Nam-Hun; Park, Seung-Kyu; Kim, 
Jeong-Cheol. Antimicrobial composition comprising silver 
zeolite, Houttuynia cordata extract and triclosan, filter for 
indoor air quality applying the same and manufacturing 
method thereof. PCT Int. Appl. (2007), 16 pp. CODEN: 
40 PIXXD2 WO 2007074957 Al 20070705 CAN 147:125938 
AN 2007:728884; 
Belcheva, Nadya; Kennedy, John. Antimicrobial medical 
devices with adherence-enhancing agents. U.S. Pat. Appl. 
Publ. (2007), 8 pp. CODEN: USXXCO US 2007207189 Al 
45 20070906 AN 2007:993759. 
Knappenberger, Kyle; Martin, Lisa; Malchesky, Paul S. 
Organic biocidal decontamination compositions. PCT Int. 
Appl. (2006),19 pp. CODEN: PIXXD2 WO 2006085975A2 
20060817 CAN 145:235978 AN 2006:817656. 
Human "carbonyl reductase" is believed to comprise sev- 50 
eral isoenzymes, which are members of the short-chain dehy-
drogenase/reductase superfamily and monomeric or tet-
rameric with subunit molecular weight of approximately 30 
kDa. Carbonyl reductase uses NAD PH, and may have physi-
010gica roles including quinone detoxification or other roles. 55 
Also triclosan, hexachlorophene, and dichlorophene are 
known anti-neoplastic agents. See, for example: 
Fischer, Frank J.; Miller, Jessica Watts; Andrews, Marvin 
O. Implantable medical device with anti-neoplastic drug. 
U.S. Pat. Appl. Publ. 200652757 (Mar. 9,2006), 12 pp., 
Oh, Sang Taek. Pharmaceutical composition for treating 
Multiple studies point to human carbonyl reductase (such 
as carbonyl reductase 1) having a role in the production of the 
anthracycline metabolites believed to cause cardiotoxic side 
effects in cancer patients either near the time of the chemo-
therapy or at some later time. This disease or condition of 60 
cardiotoxicity related to anthracycline drugs is briefly 
described above in the Related Art Section. Also, see FIG. 2 
for one example of a mechanism of carbonyl reductase reduc-
tion of an anti-cancer anthracycline to a cardiotoxic alcohol 
metabolite. C13-hydroxy-metabolites are believed to be the 65 
principle cardiotoxic agents resulting from enzyme action 
upon anthracyclines. 
cancer containing hexachlorophene capable of inhibiting 
wntlbeta-catenin response transcription. Repub. Korean 
Kongkae Taeho Kongbo (2006), No pp. given. CODEN: 
KRXXA7 KR2006124031A20061205 CAN 147:79443AN 
2007:703062. 
Westwick, John K.; Yu, Helen; Owens, Stephen; Mac-
Donald, Mamie L. Drugs for the treatment of neoplastic 
disorders. (Odyssey Thera, Inc., USA). U.S. Pat. Appl. Publ. 
20060009506 (Jan. 12,2006),21 pp. CODEN: USXXCO US 
2006009506 Al 20060112. 
To the inventors' knowledge, however, triclosan, hexachlo-
rophene, or dichlorophene have not been used in any process 
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rophene, dichlorophene and compounds with the biphenyl 
compound core structure (FIG. 3F), or a mixture of some or 
all thereof. The first and second pharmaceutical compositions 
may be administered at the same time, or may be adminis-
tered at nearly the same time (for example, within 15 minutes 
or less), or preferably within a few hours of each other (for 
example, within 2 hours or less). It may be beneficial to treat 
the patient with triclosan, hexachlorophene, dichlorophene, 
and/or compounds with the biphenyl compound core struc-
for improving efficacy of drugs used in cancer treatment offor 
treating or preventing side effects of cancer treatment or 
cardiotoxicity. Further, to the inventors' knowledge, tri-
closan, hexachlorophene, or dichlorophene have not been 
previously reported as carbonyl reductase inhibitors. The 
inventors believe that said effective and safe doses may be 
found without undue experimentation by one of skill in the art 
after reading this disclosure, especially in view of literature 
regarding known uses (as anti-biotics and anti-neoplastic 
agents) of triclosan, hexachlorophene, and dichlorophene. 10 ture (FIG. 3F) prior to anthracycline therapy (for example, 
two hours or less prior to anthracycline treatment), to block 
carbonyl reductase before administration of the anthracycline 
drug(s). 
In use, one or more of the preferred compounds, triclosan, 
hexachlorophene, dichlorophene and compounds with the 
biphenyl compound core or "general" structure (FIG. 3F) 
may be used in a pharmaceutical composition, which may 
also comprise one or more of the anthracycline drugs and/or 15 
other chemotherapy drugs or other medicines that may be 
beneficial to the cancer patient. Preferably, the triclosan, 
hexachlorophene, dichlorophene and compounds with the 
biphenyl compound core structure (FIG. 3F) and anthracy-
cline compositions are given at levels that produce the desired 20 
anti-cancer effects without the cardiotoxicity side effects. 
Therefore, the relative compositions may be changed for 
different anthracyclines and/or for different patients and/or 
for different cancers. The methods include treatment of, or 
treatment of side effects, for all cancers for which anthracy- 25 
clines are used. Embodiments of the invention therefore 
Inhibition Data 
Triclosan, hexachlorophene, and dichlorophene were 
tested as possible inhibitors for carbonyl reductase. Triclosan 
and hexachlorophene (See FIGS. 3C and E) were found to be 
uncompetitive inhibitors against the carbonyl substrate, with 
triclosan being one of the most potent carbonyl reductase 
inhibitors known to date. Dichlorophene (See FIG. 3D) was 
found to be a noncompetitive inhibitor of carbonyl reductase 
at 50 flM NADPH and an uncompetitive inhibitor at 300 flM 
NADPH. See FIG. 4-6, portraying the lIratevs. lImenadione 
include a pharmaceutical composition comprising at least one 
anthracycline compound and triclosan, hexachlorophene, 
dichlorophene and compounds with the general core structure 
depicted in FIG. 3F or a mixture of some or all thereof. The 
inventor envisions that there may be analogs or derivatives of 
triclosan, hexachlorophene, dichlorophene and compounds 
with the biphenyl compound core structure (FIG. 3F) that also 
may be effective in compositions and methods of the inven-
tion. For example, the compositions may include anthracy-
cline compounds selected from the group consisting of adria-
mycinldoxorubicin, daunorubicinldaunomycin, epirubicin, 
idarubicin, and a mixture of two or more thereof. 
concentration studies done with dichlorophene, hexachlo-
rophene, and triclsosan, respectively. The data in FIGS. 4-6 
show changes in y-intercept, while only the data in FIG. 4, 
show changes in slope. To those skilled in the art, it will be 
evident that dichlorophene exhibits noncompetitive inhibi-
tion against menadione, while hexachlorophene and tricosan 
30 exhibit uncompetitive inhibition against varied menadione. 
As shown in FIG. 7, triclosan has the lowest inhibition con-
stant (0.23 flM) and is therefore the over 52 times more potent 
in its inhibition than is hexachlorophene. Therefore, while 
compositions comprising triclosan are preferred, composi-
35 tions comprising hexachlorophene and dichlorophene are 
also included in embodiments of the invention and are also 
While the preferred patients are humans, animals may also 
benefit from the compositions and methods. Embodiments of 40 
the invented method may be for preventing or treating car-
diotoxicity associated with anthracycline cancer chemo-
therapy in a mammal in need thereof, wherein the method 
comprises administering to the mammal a composition com-
prising an effective amount of a pharmaceutical composition 45 
comprising at least one anthracycline compound and at least 
one compound or mixture selected from the group consisting 
of triclosan, hexachlorophene, dichlorophene, compounds 
with the biphenyl compound core structure (FIG. 3F), a mix-
ture of some of all of said compounds, an analog and/or 50 
derivative of said compounds, and mixtures of two or more 
thereof. Effective amounts will be determined by methods 
known to those of skill in the art. Examples of anthracycline 
compounds include adriamycinldoxorubicin), daunorubicinl 
daunomycin, epirubicin, idarubicin, and a mixture of two or 55 
more thereof. 
Instead of, or in addition to, administering a pharmaceuti-
cal composition including both anthracycline(s) and tri-
closan, hexachlorophene, dichlorophene and compounds 
with the biphenyl compound core structure (FIG. 3F), sepa- 60 
rate pharmaceutical compositions may be used. For example, 
methods may include preventing or treating a disease or con-
dition associated with carbonyl reductase in a mammal in 
need thereof by administering to the manm13l a first pharma-
ceutical composition comprising at least one anthracycline 65 
compound; and also administering to the mammal a second 
pharmaceutical composition comprising triclosan, hexachlo-
expected by the inventors to be beneficial in the methods of 
the invention. The inhibition patterns noted in FIG. 7 are 
further described/explained as follows: 
a. Regarding note "a" in FIG. 7: Studies were done with a 
fixed NADPH concentration of flM 50, varied menadione 
concentrations ranging from 12 to 125 flM in 100 mM sodium 
phosphate buffer, pH=7.0. 
b. Regarding note "b" in FIG. 7: The data fit best to the 
uncompetitive inhibition model 
wherein A is the concentration of menadione, I is the inhibitor 
concentration, V is the maximal velocity, Km is the Michaelis 
constant for mendadione and Kii is the intercept inhibition 
constant. 
c. Regarding note "c" in FIG. 7: The data fit best to the 
noncompetitive inhibition model 
VA 
wherein A is the concentration of menadione, I is the inhibitor 
concentration, V is the maximal velocity, Km is the Michaelis 
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constant for menadione, Kii is the intercept inhibition con-
stant, and Kis is the slope inhibition constant. 
d. Regarding note "d" is FIG. 7: The study was done with 
a fixed NADPH concentration of 300 flM and varied mena-
dione as described above. 
From the above inhibition patterns, the inhibitors triclosan, 
hexachlorophene, and dichlorophene most likely bind to the 
free enzyme and!orthe enzyme-NADP+ binary complex and! 
or the enzyme-menadione-NADPH ternary complex, as illus-
trated in FIG. S. It is expected that substrate carbonyls should 10 
not appreciably compete against the preferred inhibitors at 
these sites. Thus, said preferred inhibitors according to the 
invention are expected to remain available for, and will effec-
tively carry out, inhibition of the mechanism that would oth-
erwise result in lower efficacy of anthracycline(s) drugs and 15 
in cardiotoxic compounds. 
In a breast cancer cell line, MDA, triclosan was shown to 
decrease the doxorubicin ICso for cell killing. It appears from 
the graph in FIG. 9, that it is possible to increase the cell 
killing efficacy of doxorubicin by about 4-fold in breast can- 20 
cer cells. FIG. 9 illustrates the large decrease in ICso ofDoxo-
rubicin when 40 flM triclosan is used compared to 0 (zero) flM 
triclosan (approximately 380 nM reduced to approximately 
145 nM), and the additional but smaller decrease in ICso of 
Doxorubicin when 60 flM triclosan is used compared to 40 25 
flM triclosan (approximately 145 nM reduced to approxi-
mately 95 nM), and the additional but even smaller decrease 
in ICso of Doxorubicin when 80 flM triclosan is used (ap-
proximately 95 nM reduced to approximately 85 nM). The 
reduction in ICso for doxorubicin appears to have a lower 30 
limit of about 85 nM when 80 flM triclosan is used. 
Although this invention has been described above with 
reference to particular means, materials and embodiments, it 
is to be understood that the invention is not limited to these 
disclosed particulars, but extends instead to all equivalents 35 
within the broad scope of the following claims. 
The invention claimed is: 
1. A pharmaceutical composition comprising at least one 
anthracycline compound selected from the group consisting 
ofadriamycin, daunomycin, daunorubicin, doxorubicin, epi- 40 
rubicin, idarubicin, and mixtures of two or more thereof, and 
10 
3. A method for reducing effective doses of anthracycline 
effective for cancer chemotherapy in a human in need thereof, 
the method comprising: 
administering to the human a composition comprising an 
effective amount of a pharmaceutical composition com-
prising at least one anthracycline compound selected 
from the group consisting of adriamycin, daunomycin, 
daunorubicin, doxorubicin, epirubicin, idarubicin, and 
mixtures of two or more thereof, and at least one enzyme 
inhibitor lowering effective doses of anthracycline, said 
at least one enzyme inhibitor comprising a human car-
bonyl reductase enzyme inhibitor selected from the 
group consisting oftriclosan, hexachlorophene, dichlo-
rophene, and mixtures of two or more thereof, and 
exhibits a KII value in the range of 0.23-78 microMolar. 
4. The method of claim 3, further comprising reducing 
cardiotoxicity associated with anthracycline cancer chemo-
therapy by means of said at least one enzyme inhibitor inhib-
iting human carbonyl reductase. 
5. A method for improving efficacy of anthracycline che-
motherapy by inhibiting carbonyl reductase in a human, the 
method comprising: 
administering to the human a first pharmaceutical compo-
sition comprising at least one anthracycline compound 
selected from the group consisting of adriamycin, 
daunomycin, daunorubicin, doxorubicin, epirubicin, 
idarubicin, and mixtures of two or more thereof; and, 
also administering to the human a second pharmaceutical 
composition comprising an enzyme inhibitor compris-
ing at least one carbonyl reductase enzyme inhibitor 
compound, wherein said at least one carbonyl reductase 
enzyme inhibitor compound is selected from the group 
consisting of triclosan, hexachlorophene, dichlo-
rophene, and mixtures of two or more thereof, and 
wherein said at least one enzyme inhibitor exhibits a KII 
value in the range of 0.23-78 micro Molar. 
6. A method as in claim 5, wherein said second pharma-
ceutical composition is administered at the same time as said 
first pharmaceutical composition. 
7. A method as in claim 5, wherein said second pharma-
ceutical composition is administered within two hours or less 
of said first pharmaceutical composition. 
at least one carbonyl reductase enzyme inhibitor compound 
selected from the group consisting of triclosan, hexachlo-
rophene, dichlorophene, and mixtures of two or more thereof, 
and wherein said at least one enzyme inhibitor exhibits a KII 
value in the range of 0.23-78 microMolar. 
S. A method as in claim 5, wherein said second pharma-
ceutical is administered prior to the first pharmaceutical com-
45 position. 
2. A composition as in claim 1 wherein said carbonyl 
reductase inhibitor compound is triclosan and exhibits a KII 
value of 0.23 microMolar. 
9. A method as in claim 5, wherein said second pharma-
ceutical is administered after the first pharmaceutical compo-
sition. 
* * * * * 
